METALS, MINING AND ENERGY
Sunshine Metals (ASX: SHN) released a robust scoping level Mining Study for an initial open pit and underground operation at Liontown in Queensland, targeting 75koz of gold at 2.96 g/t and 654koz of silver at 25.73 g/t from a 73% Indicated and 27% Inferred production profile. Using A$6,500/oz gold and A$100/oz silver, the study forecasts gross revenue of A$458M and net operating cashflow of A$162.7M, with an AISC of A$2,741/oz gold and a maximum cash drawdown of ~A$4.6M. Updated Mineral Resource and study update expected April 2026. Covered by Mining.com.au and Industry Queensland.
Falcon Metals (ASX: FAL) reported continued drilling success at Blue Moon in the Bendigo Goldfield with the latest results including visible gold intersected in hole BMDD004W1, returning 0.8m @ 86.2g/t Au, including 0.4m @ 167g/t Au from 635m. From results received, the Company has interpreted three stacked, high-grade Bendigo-style zones defined from near-surface to depth: Morning Glory, Lotus and Dahlia. Recent results have extended the Lotus Zone by a further 80m along strike, The high-grade mineralisation is now defined over a 280m strike length and remains open along strike and down-dip. Covered by Australian Resources and Investment.
Robex Resources (ASX: RXR) Managing Director and CEO Matthew Wilcox is pictured at the company’s Kiniero Gold Project in Guinea, where commercial production was achieved last week. The delivery of the first commercial gold shipment marks a major milestone for Robex and reflects the successful ramp-up of operations at the project, following strong processing plant and operating team performance. With Kiniero now in commercial operation and generating cash, the asset is positioned to support the development of Bankan as part of the company’s transformative merger with Predictive Discovery.
Lotus Resources (ASX: LOT) hosted a group of analysts and investors at its Kayelekera Uranium Project in Malawi, as part of a joint African uranium projects site visit spanning Kayelekera and Namibia. MD Greg Bittar and COO Mike da Costa joined GM – Kayelekera Gustav Du Toit and the broader team in hosting the group tour of the project, showcasing the strong progress being made as the company continues its ramp up to ~2.4Mlb pa.
Tarrina Resources (ASX: TR8) defined untested magnetic–gravity IOCG targets at its 100% owned Walparuta Copper Gold Project in South Australia following integrated 3D geological and geophysical modelling. A large coincident magnetic and gravity anomaly begins about 70m below surface and extends down dip from the historic Walparuta Mine in an area not previously drilled. Historic drilling confirmed stratabound magnetite rich breccias hosting copper and gold, and six additional coincident magnetic and gravity anomalies have been identified across the project area. Covered by The Australian and Stockhead.
Aurum Resources (ASX: AUE) extended gold mineralisation at its 2.41Moz Boundiali Gold Project in Côte d’Ivoire, with BDT3 now confirmed 600m north of the current resource model and BST1 extended an average 130m vertically below the existing MRE. High grade results at BDT3 include 9m at 8.15 g/t Au from 207m including 2m at 35.83 g/t Au, while BST1 drilling returned 10m at 2.51 g/t Au from 170m including 5m at 4.74 g/t Au. All results will be incorporated into the Q1 2026 Boundiali MRE update, with the PFS also on track for release this quarter. Covered by Business News.
Power Minerals (ASX: PNN) delivered final high-grade niobium and rare earth results from its completed shallow auger program at Santa Anna in Brazil, with mineralisation confirmed from surface to end of hole including 5m at 14,025ppm TREO with 1m at 21,381ppm TREO and 8m at 3,373ppm Nb2O5 with 1m at 8,277ppm Nb2O5; the results validate strong near surface continuity across the weathered profile and support progress toward a maiden Mineral Resource Estimate with SRK, while a 10,000m third stage drilling campaign is now underway to test deeper niobium rich phases and expand the mineralised footprint at depth. Covered by Stockhead.
Native Mineral Resources (ASX: NMR) received further results from shallow drilling at Blackjack, Queensland, which included 10m @ 7.14g/t gold from 16m and 10m @ 3.83g/t gold from 17m. Drilling was designed to confirm gold grades in areas considered previously underdefined and test the proposed outer boundaries of a new pit planned between the Blackjack Main Pit and the northern Newton Butler Pit, with more results due through February and March.
Western Yilgarn (ASX: WYX) reported significant high-grade cobalt-nickel-scandium mineralisation at its Ida Holmes Junction Project in WA. Recent rock chip sampling over E36/1028 has returned standout results including up to 2.47% Co, 1.07% Ni, 1.30% Pb and 82.5ppm Sc (126.25ppm Sc₂O₃). Covered by Stockhead.
Magmatic Resources (ASX: MAG) completed two phases of aircore and RC drilling at its Weebo Gold Project in WA. The results from the four drill programs are very encouraging, as they continue to highlight the potential of both the Ockerburry and Scone Sone prospects for discovery, as well as grow a robust pipeline of earlier stage opportunities for future drilling. Covered by Stockhead.
Lincoln Minerals (ASX: LML) sharpened its strategy to position as a discovery-focused copper company, with Minbrie on South Australia’s Eyre Peninsula at the centre, while the Company is also advancing geological mapping and surface geochemistry at Southern Eyre to define priority copper targets, progressing an MOU with Revera Energy backed by Carlyle to assess commercialisation of the 1.23Bt Eyre Magnetite Project via green hydrogen, collaborating with SCN Canada on graphite supply for small modular reactors at Kookaburra, streamlining non core assets and actively assessing complementary copper opportunities.
Vita Resources (ASX: VTA) commissioned an independent review at its ICE Copper-Gold Project in Yukon, Canada, which confirmed the presence of associated silver, cobalt and indium alongside existing copper and gold mineralisation. This finding has upgraded the project’s status to polymetallic and providing clear direction for the next phase of resource evaluation and exploration. Covered by Australian Resources and Investment.
Everest Metals’ (ASX: EMC) December 2025 aircore drilling program at the Revere Gold Project in Western Australia confirmed continuous gold mineralisation across the Big John, Armstrong and Tree Reef prospects. High-grade gold intercepts included 1m at 32.5 g/t Au from 29m and 2 g/t Au from 70m at the Big John prospect.
Resource Base (ASX: RBX) received access to the Woomera Prohibited Area (WPA) over Exploration Licence (EL7054) in South Australia by the Department of Defence. Approved activities include Resource Exploration which paves the way for the Company to execute on its proposed exploration program for the Gawler Craton.
Locksley Resources (ASX: LKY) advanced its U.S. antimony metallurgical program with Hazen Research Inc., confirming metallic antimony exceeding 99% purity via XRD and Rietveld refinement analysis. The company is progressing toll processing assessments under the Hazen MOU for available high-grade stibnite from the Desert Antimony Mine, while continuing metallurgical optimisation at Mojave. Covered by MarketOpen, Discovery Alert.
Alligator Energy (ASX: AGE) reached another key milestone at its Samphire Uranium Project, with the successful completion of both the dry and wet commissioning activities at the FRT pilot plant in South Australia. These activities have confirmed the operational readiness of the plant and mark the final technical milestone ahead of commencing operations. Covered by Market Bull, Small Caps, Stockhead, & Middle News.
Premier1 (ASX: PLC) commenced a 3,700 RC drilling program at the Mt Kersey Gold Prospect, one of several highly prospective gold targets within a 5km2 zone of known gold mineralisation at the Yalgoo Gold Project in Western Australia. The program will test a preserved 1km+ hydrothermal system identified by coincident gold and multi-element soil anomalies (Mo-Bi-Te-W-As). Drilling is expected to be completed in two weeks with assay results to follow. Covered by The West Australian.
Heavy Rare Earths’ (ASX: HRE) planning is underway for a drilling program of up to 2,500 metres at the South Ridge tin deposit, part of the Prospect Hill Project in South Australia, the state’s largest known and most advanced tin project. The program, scheduled to commence in early Q2, will include up to 20 RC and 4 DD holes, totalling approximately 2,500 metres. Covered by Stockhead & Discovery Alert.
Golden Dragon Mining (ASX: GDR) recommenced drilling at Coodardy following the successful first phase of Reverse Circulation (RC) drilling, which intersected high-grade gold close to surface at Coodardy. One of Golden Dragon’s advanced gold targets within the greater Cue Gold Project, situated in the Murchison goldfields in Western Australia.
Chariot Resources (ASX: CC9) announced a strategic investment Jiangsu Greatpower NexEnergy Technology Co., Ltd., an affiliate of Shanghai Greatpower Nickel & Cobalt Materials Co., Ltd. Chariot and Greatpower have entered into a binding subscription agreement whereby Greatpower will become a significant Chariot shareholder with potential to explore further collaboration, subject to mutual agreement and applicable regulatory approvals.
Perpetual Resources (ASX: PEC) reported exceptional high-grade caesium and lithium results from recent channel sampling completed at the Morro Grande high-grade outcrop, located within its Igrejinha Project area in Brazil’s Lithium Valley.
Tungsten Mining (ASX: TGN) is advancing its Mt Mulgine Project following a $53M placement expected to fund PFS work and support progression toward DFS and a future FID pathway. Recent international engagement included site visits to major tungsten operations and early discussions with potential downstream processing and offtake partners, alongside broader corporate initiatives positioning the Company to benefit from strengthening critical minerals supply chain demand.
FINANCIALS
Solvar (ASX: SVR) delivered a solid H1 FY26 result, reporting normalised NPAT of $20.0 million, up 5.8% on pcp, and EPS growth of 13.5% to 9.3 cents. The Group declared fully franked dividends totalling 11.0 cents per share for the half, supported by the sale of its New Zealand written-off loan book and disciplined capital management. With over $500 million in funding headroom and FY26 guidance reiterated at $36.0 million normalised NPAT, Solvar remains well positioned for continued growth.
BIOTECH
Emyria (ASX: EMD) announced Medibank Private Ltd (ASX: MPL) has further expanded its funding agreement to support screened and eligible customers accessing Emyria’s Treatment - Resistant Depression (TRD) and Post Traumatic Stress Disorder (PTSD) programs at the Company’s new Mornington Peninsula clinic in Victoria.
Neurotech International (ASX: NTI) entered a research collaboration with the University of Sydney to advance development of its proprietary cannabinoid based compound NTI164 for Rett Syndrome, with internationally recognised Rett expert Professor Wendy Gold appointed to lead detailed mechanism of action studies using human derived neuronal models that directly interrogate MECP2 deficiency and disease relevant cellular and molecular abnormalities; the program builds on Neurotech’s successful Phase 1 clinical study and aims to further characterise how NTI164 modulates key Rett associated pathways in a rare and severe neurodevelopmental disorder with significant unmet need. Covered by The Australian.
Imricor Medical Systems (ASX: IMR) announced Na Homolce Hospital in Prague will become the third site to join its VISABL-VT clinical trial, following local ethics approval. The globally recognised centre, led by Professor Petr Neužil and supported by Dr Vivek Reddy, joins leading sites in Berlin and Amsterdam, further strengthening the study’s clinical calibre. The expansion reinforces growing European momentum for Imricor’s MRI-guided VT ablation technology and marks another step toward broader adoption of interventional cardiac MRI.
Tetratherix (ASX: TTX) reported interim performance from the clinical use of its scar prevention product (TetraDerm) on patients undergoing surgeries to remove skin lesions that created incisions up to 9cm in length. The results show that when the product is laid between layers of skin tissue before final wound closure, the subsequent scar formed at the site was minimal.
BPH Global (ASX: BP8) provided an update on Project Popeye, its proprietary seaweed-based men’s health supplement program. The Company has now progressed to the final stages of completing the formulation, including confirmation of the specific ingredients and the proportions of each component. The formulation incorporates tropical green seaweed species Caulerpa lentillifera and Ulva lactuca, alongside complementary nutraceutical ingredients.
INDUSTRIALS
Bio-Gene Technology (ASX: BGT) commenced a pivotal OECD 424 acute neurotoxicity study for Flavocide®, generating essential safety data for inclusion in its regulatory dossier. The study will assess potential neurological effects in rats following oral exposure, with the dose range-finding arm completed and the main study preliminary report expected in May 2026. The results will form a core component of Bio-Gene’s APVMA registration package and broader international submissions, supporting the advancement and commercialisation of Flavocide.
TECHNOLOGY
PlaySide Studios (ASX: PLY) has expanded its publishing portfolio, signing a global publishing agreement with Swedish developer MVRX Games for upcoming co-op adventure title Dew, slated for PC and Console release in 2028. MVRX’s team includes former lead developers of the multi-million selling Unravel franchise, bringing proven creative pedigree to the project. Under the agreement, PlaySide will fund development milestones and lead global publishing, marketing and distribution, in return for a share of net revenues.
CORPORATE NEWS
Nexalis Therapeutics Ltd (ASX: NX1) formally changed its name from InhaleRx Limited following shareholder approval at a 29 January 2026 General Meeting and receipt of ASIC’s Certificate of Change of Name. The Company’s ASX ticker changed to NX1, effective on 17 February 2026.
Chimeric Therapeutics (ASX: CHM) appointed experienced biotechnology executive and cell therapy specialist Dr Bradley Glover as Non-Executive Chair, following a global search process. Dr Glover brings more than 20 years’ experience across global biopharmaceuticals and CAR T programs, including senior roles at Kite Pharma, Genentech and Roche. Phillip Hains has retired as CFO and Joint Company Secretary and will remain on the board during transition. Aaron Laurita has been appointed Chief Financial Officer, with Nathan Jong continuing as Company Secretary and ASX contact.
North Stawell Minerals (ASX: NSM) announced that following a strategic review of North Stawell Minerals’ portfolio and an assessment of the internal experience and capabilities of both the board and management team, it will continue to pursue the opportunities within its highly prospective Stawell Corridor projects while also reviewing and assessing other project opportunities at both exploration and development level, that fall within the scope of the Company’s capabilities.
ReNerve (ASX: RNV) received a $517,133 R&D Tax Incentive refund from the Australian Tax Office under the Federal Government’s R&D Tax Incentive Scheme, strengthening its cash position as it advances its proprietary biomaterial and medical device programs targeting peripheral nerve injury repair; during FY25 the Company progressed development across its portfolio, including projects aimed at improving surgical handling and reducing complications such as scarring and infection, with the refund to support ongoing product development and its commercialisation roadmap.
Krakatoa Resources (ASX: KTA) strengthened its technical and operational leadership team with the appointment of Owen Mihalop as Technical Consultant and Graham Wall as Country Operations Manager, ahead of the 2026 exploration season at its high-grade antimony–gold Zopkhito Project in Georgia. Covered by Mining.com.au.
Paradigm Biopharmaceuticals (ASX: PAR) completed the drawdown of Tranche 3, valued at US$5 million, under its US$27 million Convertible Note Facility with Obsidian Global Partners, LLC. The Tranche 3 drawdown provides additional working capital to support the continued execution and scaling of Paradigm’s global Phase 3 clinical trial (PARA_OA_012), evaluating injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis, as the Company approaches the planned 50% recruitment milestone.
-1.png?upscale=true&width=1120&upscale=true&name=Weekly%20Wrap%20section%20dividers%20(1200%20%C3%97%20180px)-1.png)
